Skip to main content

Table 11 (A) Quality of life of non- metastatic gastric cancer, (patient’s received intervention and chemotherapy simultaneously). (B) Median difference before–after of quality of life

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

  Mean
(before)
Std.
deviation
Std.
error
P-value Mean
(after)
Std.
deviation
Std.
deviation
P-value
(A) Quality of life in patients with non-metastatic gastric cancer
Global quality
(BCc1 nanomedicine)
38.29 10.045 3.797 0.200 37.57 11.267 4.259 0.200
Global quality
(Placebo)
50.75 10.931 3.155 0.200 54.58 12.176 3.515 0.200
  Mean* Std. deviation Std. error mean P-value
(B) Median difference (beforeafter) of quality of life
Quality of BCc1 (before–after) 0.714 6.184 2.337 0.077
Quality of Placebo (before–after) − 3.833 5.441 1.571 0.033
  1. * Higher score show better global quality of life